# OnCo record paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021" ;
schema:name "PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer"@en ;
schema:description "Three different PD-L1 tests run on the same 614 IMpassion130 tumours called 46, 75 and 73 percent of them positive and agreed with each other only about 69 percent of the time; the benefit of atezolizumab was concentrated in the tumours all three called positive."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2021"^^xsd:gYear ;
schema:author "Rugo HS, Loi S, Adams S, et al." ;
onco:related , ;
onco:cancers , ;
onco:technologies ;
onco:targets ;
onco:drugs , , , , ;
onco:companies ;
onco:terms , , ;
onco:trials , ;
onco:people , , , ;
onco:bottlenecks , ;
onco:journals .